RenovoRx, Inc.
General ticker "RNXT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $43.6M (TTM average)
RenovoRx, Inc. does not follow the US Stock Market performance with the rate: -26.0%.
Estimated limits based on current volatility of 4.2%: low 0.90$, high 0.98$
Factors to consider:
- Total employees count: 8 (-11.1%) as of 2023
- Top business risk factors: Limited operating history, Significant losses, Third-party risks, Labor/talent shortage/retention, Service disruptions
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.59$, 1.66$]
- 2026-12-31 to 2027-12-31 estimated range: [0.55$, 1.57$]
Financial Metrics affecting the RNXT estimates:
- Positive: with PPE of -2.7 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of -0.01 > -0.60
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term RNXT quotes
Long-term RNXT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.04MM | $1.12MM |
| Operating Expenses | $11.40MM | $11.01MM | $13.63MM |
| Operating Income | $-11.40MM | $-10.97MM | $-12.51MM |
| Non-Operating Income | $1.16MM | $2.16MM | $1.34MM |
| R&D Expense | $5.67MM | $6.03MM | $6.27MM |
| Income(Loss) | $-10.23MM | $-8.81MM | $-11.17MM |
| Net Income(Loss)* | $-10.23MM | $-8.81MM | $-11.17MM |
| Stockholders Equity | $-3.00MM | $4.48MM | $5.42MM |
| Inventory | $0.00MM | $0.00MM | $0.19MM |
| Assets | $1.47MM | $8.12MM | $8.10MM |
| Operating Cash Flow | $-10.26MM | $-9.12MM | $-10.97MM |
| Capital expenditure | $0.00MM | $0.01MM | $0.00MM |
| Investing Cash Flow | $2.03MM | $-0.01MM | $-0.00MM |
| Financing Cash Flow | $5.01MM | $15.12MM | $10.85MM |
| Earnings Per Share** | $-0.50 | $-0.37 | $-0.32 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.